Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Non-Current Assets (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Other Non-Current Assets for 2 consecutive years, with $110000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 97.28% to $110000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110000.0 through Dec 2025, down 97.28% year-over-year, with the annual reading at $110000.0 for FY2025, 97.28% down from the prior year.
  • Other Non-Current Assets hit $110000.0 in Q4 2025 for Prelude Therapeutics, roughly flat from $110000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.0 million in Q2 2024 to a low of $110000.0 in Q1 2025.